Nyxoah (NYXH) earnings call transcripts

Management framed the call around accelerating U.S. launch traction, stronger patient funnel indicators, and a financing that removes near-term balance-sheet pressure. 180 active U.S.

Management framed Q1 as launch execution improving, with commercial reimbursement stable and investment redirected toward U.S. growth while preserving cash discipline. 15 additional U.S.

Management framed 2025 as a focused U.S. launch, with early account activation supporting confidence while reimbursement coding continues to mature.

Management framed the call around an unexpectedly fast U.S. launch, early reimbursement validation, and execution rather than near-term financial scale.